All In MedTech

Device Trial Radar · NCT02673697

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease

Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 914 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

914

Actual

Start

Mar 22, 2016

Primary completion

Jan 17, 2020

Study completion Jul 31, 2020

Sponsor

Lead sponsor
Corcym S.r.lNot on our public-company list
Sponsor type
Industry
First posted
Feb 4, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, randomized, stratified non blinded multi-center, international, post market trial assessed in a non-inferiority study. The trial has a flexible sample size that will be determined adaptively. The trial will enroll up to 1234 subjects, but accrual may stop earlier at approximately 900 or 1050 subjects These subjects will be enrolled at approximately 60 worldwide investigational sites where the device is commercially available The primary objective of this trial is to test the safety and efficacy of Perceval versus standard sutured stented bioprosthetic aortic valves among the intended trial population.

Conditions

  • Aortic Valve Disease
  • Aortic Stenosis

Interventions

  • Perceval valveDevice

    Sutureless Aortic Biological Valve

  • other stented biological valveDevice

    Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Freedom From Major Adverse Cardiac and Cerebrovascular Events (MACCE)Time frame: 1 year post-operatively

Locations

47 sites in 12 countries. Site status is shown where the registry gives one.

  • St. Vincent Heart Center of Indiana

    Indianapolis, Indiana

  • Maine Medical Center

    Portland, Maine

  • Heart and Vascular Institute, Cleveland Clinic

    Cleveland, Ohio

44 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.